A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study).

Ther Adv Med Oncol · 2024 · PMC10804904 · PMID 38264520

Europe PMC DOI

hedged sentence

0.1500

closest p · 3.0× alpha

0.1500

boldest claim

The sentences

a trend toward significancep = 0.15not close (p > 0.1)

Moreover, the percentage of patients with detectable ARv7 in their liquid biopsies decreased from 57% to 25% and 15% and was null in patients classified as PD, SD, PR, and CR, respectively, thus mirroring the degree of response, although only a trend toward significance was observed ( p = 0.15).

also in 3,729 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.